There is also a story on Reuters about Eli Lilly & Co and theirdrug Evista. It is a selective estrogen receptor modulator which is what tamoxifen is classed as.
In reference to PARS I picked this up on the YAHOO BB
<<Lotemax, Alrex, and LotemaxT pars98
Apr 3 1998
9:53PM EST
Lotemax will be introduced at a national surgery convention in San Diego on April 20th. The formal launch though will not
commence until sometime in May and both Lotemax and Alrex will be launched at the same time. Product is already in the hands of some
pharmacists and drug wholesalers. The formal launch won't be until May because 1. You must get the salesforce trained and updated on the
drug. 2. Must insure that there is sufficient product ready for distribution so that upon launch, and B&L will be putting all
there resources behing this launch, there will be no interuption in the sales channel. Also, Lotemax T looks to be very promising
as its main competitor, Tobradex, which is Tobramyacin and dexi-something, has better than 50% market share and thus far,
Lotemax T has a better safety profile and effectiveness vs. Tobradex. Also, though B&L won't officially comment on this yet, they
believe the market for Alrex is much greater than currently being forcasted. >>
The writer is using Pars98 as a handle so I'm wondering if there is any compnay affiliation? Probably not.
Steve
ÿ |
